Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
NDC API
0
VMF
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Finished Drug Prices
NA
1. 5-chloro-2,4-dihydroxypyridine
2. 5-chloro-4-hydroxy-2(1h)-pyridinone
1. 103766-25-2
2. Gimestat
3. 5-chloro-2,4-dihydroxypyridine
4. 5-chloropyridine-2,4-diol
5. 5-chloro-4-hydroxy-2(1h)-pyridone
6. 5-chloro-4-hydroxy-2(1h)-pyridinone
7. Gimeracil [inn]
8. 5-chloro-4-hydroxy-1h-pyridin-2-one
9. 5-chloro-2,4-pyridinediol
10. 5-chloro-2-hydroxypyridin-4(1h)-one
11. 2(1h)-pyridinone, 5-chloro-4-hydroxy-
12. 5-chloro-4-hydroxy-2-pyridone
13. Ua8se1325t
14. 5-chloro-4-hydroxypyridin-2(1h)-one
15. Mfcd08458352
16. 1349387-07-0
17. Ncgc00181011-01
18. Dsstox_cid_26799
19. Dsstox_rid_81914
20. Dsstox_gsid_46799
21. Cdhp Compound
22. Cas-103766-25-2
23. Unii-ua8se1325t
24. Gimeracil (cdhp)
25. Gimeracil (jan/inn)
26. Gimeracil [jan]
27. Gimeracil [mi]
28. Gimeracil [who-dd]
29. Gimeracil Impurity 1
30. Gimeracil [ema Epar]
31. Schembl124438
32. Ts-1 (tn)
33. Chembl1730601
34. Dtxsid8046799
35. Gimeracil, >=98% (hplc)
36. Chebi:31652
37. Amy2406
38. Teysuno Component Gimeracil
39. Hms3655b15
40. Act04735
41. Bcp05824
42. Tox21_112661
43. Ac-475
44. Stl452964
45. Zinc13831809
46. Gimeracil Component Of Teysuno
47. Akos006346735
48. Akos015891515
49. Akos026749993
50. Tox21_112661_1
51. Bcp9000727
52. Ccg-266172
53. Cs-1822
54. Db09257
55. Ks-5133
56. Ncgc00181011-02
57. Hy-17469
58. Sy029154
59. Ft-0645353
60. S2055
61. Sw219483-1
62. D01846
63. Ab01566858_01
64. 766g252
65. A800802
66. A935098
67. Sr-01000945072
68. Q-100034
69. Sr-01000945072-1
70. Q22075887
Molecular Weight | 145.54 g/mol |
---|---|
Molecular Formula | C5H4ClNO2 |
XLogP3 | -0.1 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 2 |
Rotatable Bond Count | 0 |
Exact Mass | 144.9930561 g/mol |
Monoisotopic Mass | 144.9930561 g/mol |
Topological Polar Surface Area | 49.3 Ų |
Heavy Atom Count | 9 |
Formal Charge | 0 |
Complexity | 207 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Gimeracil is used as an adjunct to antineoplastic therapy. When used within the product Teysuno, gimeracil is indicated for the treatment of adults with advanced gastric (stomach) cancer when given in combination with cisplatin.
Absorption
Mean 5-FU maximum plasma concentration (Cmax) and area under the concentration-time curve (AUC) values were approximately 3-fold higher after Teysuno administration than after administration of tegafur alone, despite a 16-fold lower Teysuno dose (50 mg of tegafur) compared to tegafur alone (800 mg), and are attributed to inhibition of DPD by gimeracil. Maximum plasma uracil concentration was observed at 4 hours, with a return to baseline levels within approximately 48 hours after dosing, indicating the reversibility of the DPD inhibition by gimeracil. After administration of a single dose of 50 mg Teysuno (expressed as tegafur content), median Tmax for Teysuno components tegafur, gimeracil, and oteracil was 0.5, 1.0, and 2.0 hours, respectively.
Route of Elimination
Following a single dose of Teysuno, approximately 3.8% to 4.2% of administered tegafur, 65% to 72% of administered gimeracil, and 3.5% to 3.9% of administered oteracil were excreted unchanged in the urine.
Volume of Distribution
Although no intravenous data are available for Teysuno in humans, the volume of distribution could be roughly estimated from the apparent volume of distribution and urinary excretion data as 16 l/m2, 17 l/m2, and 23 l/m2 for tegafur, gimeracil and oteracil, respectively.
Following a single dose of Teysuno, T1/2 values ranged from 6.7 to 11.3 hours for tegafur, from 3.1 to 4.1 hours for gimeracil, and from 1.8 to 9.5 hours for oteracil.
Gimeracil's main role within Teysuno is to prevent the breakdown of [DB00544] (5-FU), which helps to maintin high enough concentrations for sustained effect against cancer cells. It functions by reversibly blocking the enzyme dihydropyrimidine dehydrogenase (DPD), which is involved in the degradation of 5-FU.
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Gimeracil manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Gimeracil, including repackagers and relabelers. The FDA regulates Gimeracil manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Gimeracil API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Gimeracil manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Gimeracil supplier is an individual or a company that provides Gimeracil active pharmaceutical ingredient (API) or Gimeracil finished formulations upon request. The Gimeracil suppliers may include Gimeracil API manufacturers, exporters, distributors and traders.
click here to find a list of Gimeracil suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Gimeracil DMF (Drug Master File) is a document detailing the whole manufacturing process of Gimeracil active pharmaceutical ingredient (API) in detail. Different forms of Gimeracil DMFs exist exist since differing nations have different regulations, such as Gimeracil USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Gimeracil DMF submitted to regulatory agencies in the US is known as a USDMF. Gimeracil USDMF includes data on Gimeracil's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Gimeracil USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Gimeracil suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Gimeracil Drug Master File in Korea (Gimeracil KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Gimeracil. The MFDS reviews the Gimeracil KDMF as part of the drug registration process and uses the information provided in the Gimeracil KDMF to evaluate the safety and efficacy of the drug.
After submitting a Gimeracil KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Gimeracil API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Gimeracil suppliers with KDMF on PharmaCompass.
Gimeracil Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Gimeracil GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Gimeracil GMP manufacturer or Gimeracil GMP API supplier for your needs.
A Gimeracil CoA (Certificate of Analysis) is a formal document that attests to Gimeracil's compliance with Gimeracil specifications and serves as a tool for batch-level quality control.
Gimeracil CoA mostly includes findings from lab analyses of a specific batch. For each Gimeracil CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Gimeracil may be tested according to a variety of international standards, such as European Pharmacopoeia (Gimeracil EP), Gimeracil JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Gimeracil USP).
LOOKING FOR A SUPPLIER?